Colossal Laboratories & Biosciences stock $15.75 USD
Private-market facts for current and former Colossal Laboratories & Biosciences employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
Colossal Biosciences uses gene editing and synthetic biology to de-extinct species like the woolly mammoth and the dodo, while developing applications of its technology for conservation and human healthcare.
Selling Colossal Laboratories & Biosciences shares
Why shareholders consider selling
Shareholders in Colossal Laboratories & Biosciences may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Colossal Laboratories & Biosciences does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Colossal Laboratories & Biosciences stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Colossal Laboratories & Biosciences shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Colossal Laboratories & Biosciences shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round, its reported $10B valuation and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Colossal Laboratories & Biosciences shareholders
Exploring equity in Colossal Laboratories & Biosciences often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Colossal Laboratories & Biosciences most recently raised a Series B round . The company was valued at $10B. Total funding raised to date is approximately $235M.
Lead investors in this round include Breyer Capital and In-Q-Tel.
Founders & company background
Colossal Laboratories & Biosciences was founded in 2021 by Ben Lamm, George Church and is headquartered in Dallas, TX.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Colossal Laboratories & Biosciences still a private company?
- Yes, Colossal Laboratories & Biosciences is currently a private company.
- What is Colossal Laboratories & Biosciences's latest funding round?
- Colossal Laboratories & Biosciences's most recent known round is Series B.
- What is Colossal Laboratories & Biosciences's valuation?
- Colossal Laboratories & Biosciences's latest reported valuation is $10B.
- Who are the investors in Colossal Laboratories & Biosciences?
- Notable investors include Breyer Capital, In-Q-Tel.
- Can I sell my Colossal Laboratories & Biosciences stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Colossal Laboratories & Biosciences stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Colossal Laboratories & Biosciences data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.